Achillion Pharmaceuticals

INVESTORS

Press Releases

 
Press Releases
  Date Title View
Feb 8, 2008
NEW HAVEN, Conn., Feb 8, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overvi...
PDF
Jan 31, 2008
NEW HAVEN, Conn., Jan 31, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced positive safety and efficacy results from two ongoing Phase 2 clinical trials studying elvucita...
PDF
Nov 26, 2007
NEW HAVEN, Conn., Nov 26, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Dr. Elizabeth A. Olek as vice president and chief medical officer. Dr. Olek ...
PDF
Nov 2, 2007
NEW HAVEN, Conn., Nov 2, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presentin...
PDF
Nov 2, 2007
NEW HAVEN, Conn., Nov 2, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter ended September 30, 2007. For the third quarter of 2007, th...
PDF
Oct 15, 2007
NEW HAVEN, Conn., Oct 15, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced preliminary 12-week results from an ongoing Phase 2 clinical trial studying elvucitabine in pat...
PDF
Sep 17, 2007
NEW HAVEN, Conn., Sep 17, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overv...
PDF
Aug 22, 2007
NEW HAVEN, Conn., Aug 22, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of David P. Wright to its Board of Directors. Mr. Wright, who is President and ...
PDF
Aug 8, 2007
NEW HAVEN, Conn., Aug 8, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and six months ended June 30, 2007. For the six months ende...
PDF
Jul 27, 2007
NEW HAVEN, Conn., Jul 27, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals Inc. (Nasdaq:ACHN) expects to release its results for the second quarter ended June 30, 2007 after the market closes on Wednesday, August 8, 2007. The company will host a conference call to discuss the results at 4:30 PM ET on August 8. The call ...
PDF
FirstPrevious
...
25
NextLast